Natco Pharma Limited
Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

14th August 2026

Corporate Relationship Department
M/s. BSE Ltd.
Mumbai 400 001
Scrip Code: 524816

Manager – Listing
M/s. National Stock Exchange of India Ltd
Mumbai 400 051
Scrip Code: NATCOPHARM

Dear Sir/Madam,

Sub: - Q1 FY 27 Earnings Presentation

Please find enclosed herewith the Earnings Presentation for the Quarter ended 30th June, 2026.

Thanking you

Yours faithfully

For NATCO Pharma Limited

VENKAT RAMESH CHEKURI
Digitally signed by VENKAT RAMESH CHEKURI
Date: 2026.08.14 17:35:27 +05'30'

Ch. Venkat Ramesh
Company Secretary &
Compliance Officer

Encl : as above

NATCO Pharma Limited

Earnings Presentation

Q1FY27

Disclaimer

THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF NATCO PHARMA LIMITED OR ITS SUBSIDIARIES OR JOINT VENTURES (TOGETHER, THE "COMPANY").

The material that follows is a Presentation of general background information about the Company's activities as at the date of the Presentation or as otherwise indicated. It is information given in summary form and does not purport to be complete and it cannot be guaranteed that such information is true and accurate. This Presentation has been prepared by and is the sole responsibility of the Company. By accessing this Presentation, you are agreeing to be bound by the trading restrictions. It is for general information purposes only and should not be considered as a recommendation that any investor should subscribe / purchase the Company shares.

This Presentation includes statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward- looking terminology, including the terms "believes", "estimates", "anticipates", "projects", "expects", "intends", "may", "will", "seeks" or "should" or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, aims, objectives, goals, future events or intentions. These forward-looking statements include all matters that are not historical facts. They appear in a number of places throughout this Presentation and include statements regarding the Company's intentions, beliefs or current expectations concerning, amongst other things, its results or operations, financial condition, liquidity, prospects, growth, strategies and the industry in which the Company operates.

By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Forward-looking statements are not guarantees of future performance including those relating to general business plans and strategy of the Company, its future outlook and growth prospects, and future developments in its businesses and its competitive and regulatory environment. No representation, warranty or undertaking, express or implied, is made or assurance given that such statements, views, projections or forecasts, if any, are correct or that the objectives of the Company will be achieved. There are some important factors that could cause material differences to Company's actual results. These include (i) our ability to successfully implement our strategy (ii) our growth and expansion plans (iii) changes in regulatory norms applicable to the Company (iv) technological changes (v) investment and business income (vi) cash flow projections etc. (vii) exposure to market as well as other risks.

The Company, as such, makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information or opinions contained herein. The information contained in this Presentation, unless otherwise specified is only current as of the date of this Presentation. The Company assumes no responsibility to publicly amend, modify or revise any forward-looking statements based on any subsequent development, information or events, or otherwise. Unless otherwise stated in this Presentation, the information contained herein is based on management information and estimates.

Any opinions expressed in this presentation are subject to change without notice. The presentation should not be construed as legal, tax, investment or other advice. None of the Company or any of its affiliates, advisers or representatives accepts any liability whatsoever for any loss howsoever arising from any information presented or contained in this presentation. The information contained in this presentation has not been independently verified. Furthermore, no person is authorized to give any information or make any representation which is not contained in, or is inconsistent with, this presentation. Any such extraneous or inconsistent information or representation, if given or made, should not be relied upon as having been authorized by or on behalf of the Company. Further, past performance is not necessarily indicative of future results.

This document is just a Presentation for information purposes and private circulation only and is not intended to be a "prospectus" or "offer document" or a "private placement offer letter" (as defined or referred to, as the case may be, under the Companies Act, 2013). It is clarified that this Presentation is not intended to be a document offering for subscription or sale of any securities or inviting offers from the Indian public (including any section thereof) or from persons residing in any other jurisdiction including the United States for the subscription to or sale of any securities including the equity shares of the Company or any of its subsidiaries. No part of it should form the basis of or be relied upon in connection with any investment decision or any contract or commitment to purchase or subscribe for any securities. None of the Company's securities may be offered or sold in the United States without registration under the U.S. Securities Act of 1933, as amended, except pursuant to an exemption from registration there from.

This document has not been and will not be reviewed or approved by a regulatory authority in India or by any stock exchange in India. This presentation is confidential and this presentation or any part thereof should not be used or relied upon by any other party or for any other purpose and should not be copied, reproduced, recirculated, redistributed, published in any media, website or otherwise, in any form or manner, in part or as a whole, without the express consent in writing of the Company. Any unauthorized use, disclosure or public dissemination of information contained herein is prohibited. The distribution of this presentation in certain jurisdictions may be restricted by law. Accordingly, any persons in possession of the aforesaid should inform themselves about and observe any such restrictions.

Q1FY27 - Key Business & Consolidated Financial Highlights

- Total Revenue for Q1FY27 stood at INR 7,944 Mn | International Formulations at INR 4,771 Mn | Domestic Formulations Revenue at 1,364 Mn
- Earnings Before Interest Tax Depreciation and Amortization stood at INR 2,457 Mn and EBITDA Margin at 30.9% for Q1FY27* as against 25.1% in Q4FY26
- Profit after tax for Q1FY27 stood at INR 2,065 Mn | Profit margin stood at 26%
- Earnings per share (EPS) for Q1FY27 stood at INR 11.53 per share
- Profit share from our associate Adcock Ingram Holdings Ltd for Q1FY27 stood at INR 843 Mn**
- Received Final Approval for Eribulin Mesylate Injection from U.S. FDA

*EBITDA and EBITDA Margin includes Other income
**As per holding of 35.75%; NATCO acquired additional 13.25% stake in July'2026

ADCOCK INGRAM HOLDINGS

- Established in 1890 as a pharmacy in Krugersdorp, South Africa and evolved to be one of the biggest pharmaceutical and healthcare companies on the African continent.
- Second-largest South African based pharmaceutical company in terms of private market share.
- Engages in the manufacturing, selling & marketing and distribution of healthcare products to private and public sectors in Southern Africa.
- Southern Africa: Conducts business through four commercial divisions- Prescription, OTC, Hospital & Consumer.
- Owns 3 manufacturing facilities near Johannesburg, South Africa and 49% of an Indian JV that runs 2 manufacturing facilities in India.





*As on 31-07-2026, NATCO Pharma holds a 49% stake in Adcock Ingram Holdings

CLAYVILLE
High volume oral liquids

AEROTON
Integrated steriles manufacture

adcock ingram

Q1FY27 – Segmental Performance

Revenue Breakup (INR Mn)	Q1FY27	Q1FY26	Q4FY26
API Revenue	667	526	639
Pharmaceutical Formulation			
Formulation – Domestic	1,364	107	1,087
International Formulations (Incl. profit share and subsidiaries)	4,771	1,121	5,231
Pharmaceutical Formulations Total Revenue	**6,135**	**1,228**	**6,318**
Crop Health Sciences	408	347	226
Other operating & non-operating income	734	754	986
Consolidated Total Revenue	**7,944**	**1,391**	**8,169**

Revenue Breakup (%) – Q1FY27



Revenue Breakup (%) – FY26



Consolidated Profit & Loss Statement

Profit & Loss Statement (INR Mn)	Q1FY27	Q1FY26	Q4FY26
Total Revenue	**7,944**	**13,906**	**8,169**
Total Expenses (before finance cost and depreciation)	5,487	7,579	6,115
Earnings before interest, tax, depreciation and amortization (EBITDA)	**2,457**	**6,327**	**2,054**
EBITDA margin* (%)	***30.9%***	***45.5%***	***25.1%***
Finance cost	130	32	109
Depreciation	471	576	504
Profit before tax (PBT) before exceptional items	1,856	5,719	1,441
Current and Deferred Tax	634	916	-892
Profit after tax (PAT)	**1,222**	**4,803**	**2,333**
Share of profit of associate (net of tax)	843	-	357
Net Profit	**2,065**	**4,803**	**2,690**
PAT margin (%)	***26.0%***	***34.5%***	***32.9%***
Reported Earnings per share INR - Basic and Diluted	11.53	26.84	14.96

**includes other income*

Key Product Pipeline - USA

28 Para IVs in the pipeline, with over 20 FTFs (incl. Sole and Shared)

17 Approved (either tentative or fully)

Key Sole FTFs (Para IV) in the pipeline

Brand	Molecule	Therapeutic segment/ Primary Indication
Kyprolis	Carfilzomib (10mg)	Cancer/Multiple Myeloma
Imbruvica	Ibrutinib (tablet)	Cancer/Leukaemia
Zydelig	Idelalisib	Cancer/ Blood and Bone Marrow Cancer
Lynparza	Olaparib	Ovarian/Breast Cancer
Ozempic	Semaglutide pen 8mg/3ml & 2 mg/3ml)	Diabetes
Balversa	Erdafitinib	Bladder Cancer
Wegovy	Semaglutide (all strengths)	Weight Loss
Tabrecta	Capmatinib	Cancer/ Lung Cancer

Key Para IV products in the pipeline (Filing on NCE-1) date

Brand	Molecule	Therapeutic segment/ Primary Indication
Eliquis	Apixaban	Anticogulant
Ozempic	Semaglutide pen (2 strengths)	Diabetes
Lonsurf	Trifluridine/Tipracil	Metastatic colorectal cancer
Yondelis	Trabectedin	Advanced soft-tissue sarcoma/ ovarian cancer
Calquence	Acalabrutinib	Cancer/Blood
Kyprolis	Carfilzomib 60 mg/ml	Cancer/Multiple Myeloma
Nurtec	Rimegepant	Migraine
Jevtana	Cabazitaxel	Cancer
Everysdi	Risdiplam Oral Solution	Spinal Muscular Atrophy

Data as on 30th June 2026

Our NCE | Cell & Gene Therapy Investments

1 eGenesis

- Invested US$ 8 million in a biotechnology company focused on xenotransplantation, by developing safe and effective human compatible organs for transplant
- First ever human transplant of a genetically engineered pig kidney was done in March'24
- 3 patients with end-stage kidney disease have received kidney xenotransplants; 2 patients achieved >8 months of dialysis independence
- FDA has cleared the Phase 1/2/3 clinical study for kidney xenotransplantation; initiation of 33-patient trial registration study to commence in early 2027
- FDA clearance received for Phase 1/2 clinical study for liver xenotransplantation in patients with acute-on-chronic liver failure (ACLF).

2 NRC - 2694

- NRC-2694-A is an orally administered small-molecule tyrosine kinase inhibitor discovered and developed by NATCO
- It is being tested for the treatment of Head and Neck cancer). A Phase 2 clinical trial for the treatment of Recurrent/Metastatic Head and Neck cancer who progressed on Keytruda® (Pembrolizumab manufactured by Merck & CO) has been approved by US FDA
- Currently, the patient recruitment is in progress, trial is being conducted in US and India.

3 Cellogen Therapeutics

- Invested US$ 2 million focused on advanced cellular engineering methods and gene-therapy-based approaches
- Developing Innovative third and fourth generation CAR-T cell therapies for leukemia and lymphoma genetic therapies for beta-thalassemia and sickle cell disease
- First human dosing for Leukemia will begin shortly in India
- Received GMP manufacturing approvals in India.

4 Stero Therapeutics

- Invested US$ 1 million with focus on developing novel therapy for metabolic diseases
- Focused on Cushing's syndrome with expansion into NASH
- Conducting pre-clinical animal studies.

Earnings Call Details – Q1 FY27

The Earnings call to discuss the operational and financial performance of the company with Mr. Rajeev Nannapaneni, Vice Chairman and Chief Executive Officer, Mr. Amit Parekh, Chief Financial Officer, Mr. Rajesh Chebiyam, Executive Vice President, Crop Health Sciences and Mr. Rajeev Menon – Lead, Investor Relations are as below:

Details of the Earnings call:

- *Date: 14th August 2026*
- *Time: 5.30 PM IST*
- ***Dial-in-Numbers:***
  - *India: (+91 22) 62801222 / 71158123*
  - *US: 18667462133*
  - *UK: 08081011573*
  - *Singapore: 8001012045*

Diamond pass link:

https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=8730033&linkSecurityString=43c052c9f4

Thank You

Contact:

Rajeev Menon – Investor Relations

r.menon@natcopharma.co.in / ir@natcopharma.co.in

040-23546208/ Ext: 323

https://twitter.com/pharma_natco

https://www.linkedin.com/company/natcopharma